top of page
Steve_ colour_COVER.jpg
"As a prostate cancer survivor,

​

it is a privilege to be able to contribute to a study that has the potential to deliver new methods of testing for prostate cancer that are more reliable, more accurate and less invasive than the current prostate-specific antigen (PSA) test and biopsies. Not all men with prostate cancer are as fortunate as me; I had symptoms that indicated a problem, even though my PSA result was 'normal', but many men have no symptoms at all. We need a test that clinicians and patients can trust."

ABOUT US
ReIMAGINE Graphic for website 2.png

The ReIMAGINE Consortium is a pioneering prostate cancer research programme comprising three complementary studies: ReIMAGINE[Risk], ReIMAGINE[Screening] and ReIMAGINE[Life].

​

Together, these studies aim to improve how prostate cancer is identified, detected, stratified and managed, helping to deliver more personalised care for men across the disease pathway.

 

By combining advanced imaging, biological samples, clinical data and patient involvement, the Consortium is generating evidence to support earlier detection, more accurate risk assessment and improved long-term outcomes.

Find Out More.png

The ReIMAGINE Consortium was launched with funding of £4.1 million from the Medical Research Council (MRC) and £1 million from Cancer Research UK (CRUK), as part of the MRC Stratified Medicine Initiative. More recently, the Consortium expanded with the launch of ReIMAGINE Life, supported by funding from Prostate Cancer UK (PCUK) and Cancer Research Horizons (CRH).

MRCLogo_RGB_Steve.png

© 2018 ReIMAGINE

bottom of page